BELLUS Health Inc. said it raised an additional $9.4 million after underwriters partially exercised their overallotment option in the company's IPO.
Canada's Bellus Health sold an additional 1,320,296 common shares at $7.10 apiece to the underwriters. Jefferies, Cowen and Guggenheim Securities acted as joint book-running managers, Baird as lead manager and Bloom Burton Securities as co-manager for the offering.
Gross proceeds from the IPO now stand at about $79.4 million and will help the company in research and development activities, among other things.
The biotechnology company develops therapies to treat chronic cough and other hypersensitization-related disorders.
